CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 956 enrolled
Drug / intervention
fluocinolone acetonide +2 moredrug
Likely dose
fluocinolone acetonide 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00344968
NCT00344968Phase 3Completed

A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/Day and ASI-001B 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema

Alimera Sciences·interventional·Posted Jun 27, 2006·Updated May 7, 2014

In Brief

A Phase 3 clinical trial evaluating fluocinolone acetonide, Fluocinolone Acetonide, and 1 other intervention for Diabetic Macular Edema. Completed, enrolled 956 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of an intravitreal insert of fluocinolone acetonide for the treatment of diabetic macular edema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2006
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2009
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.0 years ago

Interventions

fluocinolone acetonidedrug

0.5 mg fluocinolone acetonide intravitreal insert

Fluocinolone Acetonidedrug

0.2 mg fluocinolone acetonide intravitreal insert

Standard of care laser photocoagulationprocedure

Laser photocoagulation